Have R&D Spillovers Declined in the 21 st Century?
Fiscal Studies · 2019-12 · 40 (4) · 561-590
DOI: 10.1111/1475-5890.12195 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fiscal Studies, online erschienen am 17.02.2020. Verfasst von Brian Lucking und 2 weiteren Autor:innen. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Slow growth over the last decade has prompted policy attention towards increasing R&D spending, often via the tax system. We examine the impact of R&D on firm performance, both by the firm's own investments and through positive (and negative) spillovers from other firms. We analyse panel data on US firms over the last three decades, and allow for time‐varying spillovers in both technology space (knowledge spillover) and product market space (product market rivalry). We show that the magnitude of R&D spillovers remains as large in the second decade of the 21 st century as it was in the mid 1980s. Since the ratio of the social return to the private return to R&D is about four to one, this implies that there remains a strong case for public support of R&D. Positive spillovers appeared to temporarily increase in the 1995–2004 digital technology boom. We also show how these micro estimates relate to estimates from the endogenous growth literature and give some suggestions for future work.
Zitieren
APA
Lucking, B., Bloom, N., & Reenen, J. V. (2019). Have R&D Spillovers Declined in the 21 st Century?. Fiscal Studies, 40(4), 561-590. https://doi.org/10.1111/1475-5890.12195
Vancouver
Lucking B, Bloom N, Reenen JV. Have R&D Spillovers Declined in the 21 st Century?. Fiscal Studies. 2019;40(4):561-590. doi:10.1111/1475-5890.12195
BibTeX
@article{Lucking2019,
author = {Lucking, Brian and Bloom, Nicholas and Reenen, John Van},
title = {Have R&D Spillovers Declined in the 21 st Century?},
journal = {Fiscal Studies},
year = {2019},
volume = {40},
number = {4},
pages = {561--590},
doi = {10.1111/1475-5890.12195}
}
EUVIMED